Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer

Detalles Bibliográficos
Autores principales: Zheng, Li, Zhu, Yabi, Liu, Yangyang, Ma, Xu, Xu, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013639/
https://www.ncbi.nlm.nih.gov/pubmed/35307966
http://dx.doi.org/10.1111/1759-7714.14395
_version_ 1784688038093258752
author Zheng, Li
Zhu, Yabi
Liu, Yangyang
Ma, Xu
Xu, Fang
author_facet Zheng, Li
Zhu, Yabi
Liu, Yangyang
Ma, Xu
Xu, Fang
author_sort Zheng, Li
collection PubMed
description
format Online
Article
Text
id pubmed-9013639
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-90136392022-04-20 Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer Zheng, Li Zhu, Yabi Liu, Yangyang Ma, Xu Xu, Fang Thorac Cancer Letters to the Editor John Wiley & Sons Australia, Ltd 2022-03-20 2022-04 /pmc/articles/PMC9013639/ /pubmed/35307966 http://dx.doi.org/10.1111/1759-7714.14395 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letters to the Editor
Zheng, Li
Zhu, Yabi
Liu, Yangyang
Ma, Xu
Xu, Fang
Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer
title Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer
title_full Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer
title_fullStr Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer
title_full_unstemmed Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer
title_short Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer
title_sort pembrolizumab: a reliable second‐line treatment option for advanced esophageal cancer
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013639/
https://www.ncbi.nlm.nih.gov/pubmed/35307966
http://dx.doi.org/10.1111/1759-7714.14395
work_keys_str_mv AT zhengli pembrolizumabareliablesecondlinetreatmentoptionforadvancedesophagealcancer
AT zhuyabi pembrolizumabareliablesecondlinetreatmentoptionforadvancedesophagealcancer
AT liuyangyang pembrolizumabareliablesecondlinetreatmentoptionforadvancedesophagealcancer
AT maxu pembrolizumabareliablesecondlinetreatmentoptionforadvancedesophagealcancer
AT xufang pembrolizumabareliablesecondlinetreatmentoptionforadvancedesophagealcancer

Ejemplares similares